文献速递泌尿生殖介入CT

病态肥胖肾细胞癌患者的热消融治疗:技术、安全性与肿瘤学结局评估

Thermal Ablation of Renal Cell Carcinoma in Patients With Morbid Obesity: Assessment of Technique, Safety, and Oncologic Outcomes.
PubMed 文献 · AJR Am J Roentgenol · 2021-02-17

回顾性分析107例CT引导下肾消融的临床T1肾细胞癌患者,按BMI≥40 kg/m²(病态肥胖,34例)与BMI 18.5–24.9(正常体重,73例)分组比较。病态肥胖组手术时间、镇静剂量及辐射暴露更长/更高,肾周血肿更常见,但治疗有效性和局部复发率与正常体重组相当,5年影像观察的肿瘤学结局等效。

要点

  • 病态肥胖患者行CT引导肾消融技术可行、耐受良好且有效。
  • 病态肥胖组肾周血肿发生率高于正常体重组(p = .01)。
  • 两组治疗有效性与局部复发率相当(p = .81和p = .12)。

诊断标准与关键数值

  • 病态肥胖组手术时间较正常体重组长(p = .001)。
  • 病态肥胖组镇静剂量较正常体重组高(p = .002)。
  • 病态肥胖组辐射暴露较正常体重组高(p = .001)。
  • 病态肥胖组肾周血肿较正常体重组更常见(p = .01)。
  • 两组治疗有效性无显著差异(p = .81),局部复发无显著差异(p = .12)。

临床应用与阅片要点

  • 作者认为CT引导热消融可被视为病态肥胖肾细胞癌患者安全有效的治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Obesity is a worldwide problem that impacts patient health as well as the morbidity associated with surgical procedures. Thus, patients with morbid obesity may not be suitable candidates for curative surgery. For this patient population, thermal ablation may be an effective alternative to nephrectomy. OBJECTIVE. The purpose of this study was to determine the feasibility, oncologic outcomes, and survival of patients with morbid obesity and renal cell carcinoma treated with thermal ablation. MATERIALS AND METHODS. A retrospective analysis was performed of 107 patients treated with CT-guided renal ablation for clinical T1 renal cell carcinoma between February 2005 and December 2017. Patients were stratified into two cohorts on body mass index of ≥ 40 kg/m2 (morbidly obese) and body mass index (weight in kilograms divided by the square of height in meters) of ≥ 40 (morbidly obese) and 18.5-24.9 (normal weight). Anesthetic and radiation dosages, procedure time, residual disease, and local recurrence, and adverse events were analyzed between the two groups. Kaplan-Meier statistics were used to evaluate cancer-related outcomes for each group. RESULTS. Thirty-four patients were morbidly obese, and 73 patients had normal weight. Morbid obesity was associated with longer procedural duration (p = .001), sedative doses (p = .002) and radiation exposure (p = .001) than normal weight. Hematomas were more prevalent in patients with morbid obesity than in those of normal weight (p = .01), but treatment efficacy and local recurrences were comparable with those for normal-weight individuals (p = .81 and p = .12, respectively). Cancer-related outcomes were equivalent between the two groups based on 5 years of imaging observation data. CONCLUSION. CT-guided thermal ablation remains technically feasible, well-tolerated, and effective in patients with morbid obesity and renal cell carcinoma, with the caveat of increased risk of perinephric hematoma, anesthesia dose, and radiation exposure. CLINICAL IMPACT. CT-guided thermal ablation can be considered a safe and effective treatment for renal cell carcinoma in patients with morbid obesity.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Zhou W, Herwald SE, Uppot RN, et al. Thermal Ablation of Renal Cell Carcinoma in Patients With Morbid Obesity: Assessment of Technique, Safety, and Oncologic Outcomes. AJR Am J Roentgenol. 2021. PMID: 32755206. doi:10.2214/AJR.20.23803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。